Skip to main content

Table 2 Demographic and clinical characteristics according to alpha 1 antitrypsin genotypes

From: Alpha 1 antitrypsin distribution in an allergic asthmatic population sensitized to house dust mites

  PI*MM (n = 503) PI*MS (n = 110) PI*MZ (n = 15) PI*SS (n = 14) PI*SZ (n = 6) P value
Sex n (%) 0.525
 Male 178 (35) 35 (32) 3 (20) 6 (43) 1 (17)
 Female 325 (65) 75 (68) 12 (80) 8 (57) 5 (83)
Age, years 0.818
 Median (IQ25–75) 28 (20–38) 31 (23–38) 30 (24–38) 32 (20–36) 20.5 (19–36)
Smokers n (%) 37 (7.4) 11 (10) 4 (26.7) 2 (14.3) 0 0.0882
Intermittent asthma n (%) 191 (38) 45 (41) 4 (26.7) 9 (64.3) 4 (66.7) 0.134
Mild persistent asthma (%) 194 (38.6) 39(35.5) 6(40) 5(35.7) 2(33.3) 0.981
Moderate persistent asthma n (%) 78 (15.5) 18 (16.4) 4 (26.7) 0 0 0.303
Severe persistent asthma n (%) 39 (7.8) 8 (7.3) 1 (6.7) 0 0 0.958
Polyposis n (%) 9 (1.8) 6 (5.5) 2 (13.3) 0 0 0.104
Chronic sinusitis n (%) 24 (4.8) 3 (2.7) 2 (13.3) 2 (14.3) 1 (16.7) 0.0516
Atopic dermatitis n (%) 17 (3.4) 4 (3.6) 0 1 (7.1) 1 (16.7) 0.271
Previous pneumonia n (%) 4 (0.8) 1 (0.9) 0 0 0 1
> 3infections/year n (%) 4 (0.8) 0 0 0 0 1
Previous treatment: oral glucocorticosteroids n (%) 10 (2) 2 (1.8) 0 0 0 1
Previous treatment: immunotherapy n (%) 38 (7.6) 10 (9.1) 0 0 0 0.804
Previous treatment: omalizumab n (%) 1 (0.2) 0 0 0 0 1
  1. * Kruskal–Wallis statistic analysis for continuous non normal variables and Chi square or F-test for nominal ones